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ABSTRACT
One of the key challenges of breast cancer research is to predict whether a patient
identified with specific subtype or treated with a specific therapy is going to survive or
die. Current studies find small subsets of gene biomarkers able to accurately predict the
response to therapy. In these studies, the selected genes are not necessarily functionally
related, and hence, they may not correctly indicate the molecular mechanism behind breast
cancer survivability. Also, several studies have shown there is a very low overlap between
the different respective biomarkers subsets for the same cancer disease. To improve the
robustness of classification performance and stability of detected biomarkers, recent meth-
ods take existing knowledge on relations between genes into account in the classifier, by
aggregating functionality related genes to produce discriminative gene subnetworks called
network-biomarkers. In this paper, given a breast cancer dataset of patients with different
subtypes treated with a given therapy drug, we devised network-based machine learning ap-
proach by integrating protein protein interaction network (PPI) with gene expression data
(1) to identify the network-biomarkers of breast cancer survivability a) based on subtypes
and b) based on therapy and (2) to predict the survivability of breast cancer patients a)
based on subtypes b) treated with a therapy drug. We used the concept of seed gene for
identification of network-biomarkers with distance 2, 3 and 4 from seed gene protein and
our method found distance 3 and 4 are the distance that gives us best result for identifying
survivability of breast cancer patient based on subtype and therapy respectively. To solve
the class imbalance problem in some subtypes, we implemented ADASYN. We obtained
best classification performance using random forest where the geometric mean, F1-measure
and accuracy are respectively 0.867, 0.850 and 87.00% for subtype specific study, and 0.829,
0.807 and 83.77%, for therapy specific.
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1.1 Breast Cancer and Important Terminologies
Breast Cancer is a complex disease that starts in the cells of the breast. It comprises five [23]
to ten [7] genomics subtypes where each subtypes has distinct molecular mechanism and has
distinct clinical progression. Recent studies showed that there is extensive diversity between
and within breast cancer patients and each breast cancer shows unique characteristics. The
heterogeneity of this cancer complicates diagnosis and treatment as studies found many
patient of breast cancer undergoes with over-treatment [29]. The reason behind is thec
mutation of small number of genes called drivers whose change deregulate many biologial
processes or cellular pathways, and therefore leading to initiation and progression of breast
cancer as well as resistance to treatment [16]. Driver genes are expressed aberrantly that
confers selective growth or contain driver gene mutation [33]. Driver genes also may contain
passenger gene mutation that have no direct or indirect effect on selective growth advantage
of the cell [35]. Passenger genes are those whose deregulations or expression changes are the
by product of drivers. Thus the driver genes are those that are responsible for cancer and
the passengers have no effect on cancer but they can be present in the driver gene mutation.
Together, the drivers and their passengers are called gene biomarkers. For predicting breast
cancer classes, it is necessary to discover the biomarkers that play vital role in breast cancer
subtypes. There are 8 different kinds of biomarkers: 1) prognostic biomarkers: to predict
the development of a cancer [14], 2) diagnostic biomarkers: to predict the presence of disease
or condition of interest or the subtype of cancer [22], 3) predictive biomarkers: to predict the
survivability of patient treated with specific drug[8], 4) treatment biomarkers: to predict the
effectiveness of a treatment[24]. 5) progression biomarkers: to predict whether the cancer
is spreading or not [30], 6) monitoring biomarkers: to predict if therapy is working [25],
7) recurrence biomarkers: to predict whether the cancer will recur after sometimes or not
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[19], 8) risk biomarkers: to predict predisposition to cancer [32]. In this thesis, we focus on
finding predictive biomarkers that can identify survival of breast cancer patient.
Gene expression METABRIC dataset has been used to identify differentially expressed
genes that can predict the survival of breast cancer patient. The word METABRIC comes
by taking initial letters from Molecular Taxonomy of Breast Cancer International Consor-
tium. It is a Canada-UK project to classify breast cancer into subcategories based on their
molecular signatures so that it will be helpful for identifying optimal treatment of breast
cancer patient. Gene expression is the process by which the instruction in our DNA are
converted into a functional product, such as protein. A classifier can predict breast cancer
class from an unseen data based on previously trained data of known classes. The funda-
mental limitation of gene expression base study is that it fails to obtain robust and highly
predictive classifier across different datasets as C Soneson et al. [28] found the classifier’s
accuracy decreases dramatically when the classifier trained with the dataset of one study
and test with the dataset of another study for the same subtype. It is also found that even
for the same breast cancer subtype only a 4% gene biomarkers overlaps across different
datasets[10]. This leads to the hypothesis that adding more information with gene expres-
sion data with the genes that are functionally related can predict the breast cancer classes
and give robustness of classifier performance to the prediction model. Network-biomarkers
takes the existing knowledge on relation among genes into account by aggregating func-
tionally related genes to produce discriminative gene subnetworks. Studies showed that
network-biomarkers significantly improves the classifier performance for different datasets
and produce stable network-biomarkers [2] [3] [6] [8] [36]. In this thesis, we devised a machine
learning approach that used protein protein interaction network along with gene expression
data to find the functional relation among genes and their corresponding protein for pre-
dicting the survivability of breast cancer patient and for identifying network-biomakers for
survivability.
There are three types of therapy: chemotherapy, hormone therapy and radiotherapy.
A breast cancer patient can receive any combination of these three therapy. Even the
patient may not receive any therapy too. Chemotherapy is a medication or combination
of medication that is used to treat cancer patient. On the other hand hormone therapy
is used only for those patients who have hormone receptor positive breast cancer. The
purpose of hormone therapy is to reduce the amount of hormone estrogen in the body and
2
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to block the action of estrogen in the body. Radiotherapy uses high energy ray to damage
cancer cells and can be used externally or internally. Survival of patients are dependent
on choosing appropriate therapy and identifying appropriate biomarkers. Patient survival
also depends on subtypes as studies found that some subtypes have a higher mortality than
other subtypes [5].
In Chapter 2 we introduce our method. In Chapter 3, we talk about our experiment
and results. In Chapter 4, we discuss about our method and its limitation and Chapter 5
is our conclusion.
1.2 Problem Statement
In this thesis, given a breast cancer dataset of patients of different subtypes and treated with
different combination of chemotherapy, hormone therapy and radiotherapy , our aim is (1) to
identify the network-biomarkers of breast cancer survivability a) based on subtypes without
considering any therapy b) based on different combination of therapy but not considering
the subtypes and (2) to predict the survivability of breast cancer patients a) of different
subtypes (b) treated with different combinations of chemotherapy, hormone therapy and
radio therapy or no drug.
1.3 Motivation
Current bioinformatics methods find small subsets of gene biomarkers able to accurately
predict the response to therapy. In these studies, the selected genes are not necessarily
functionally related, and hence, they may not correctly indicate the molecular mechanism
behind breast cancer survivability. Several studies have shown the lack of robustness and
stability of currently identified biomarker subsets from different research; that is, there is
a very low overlap between the different respective biomarkers subsets for the same cancer
disease, and hence a subset identified in one study yields low performance on data used
in another study. This lack of robustness and stability is because of insufficient patient
sample size [18] that is the number of features are generally too high compared to number
of samples and generally, there are very few samples available for cancer study, the inherent
measurement noise in microarray experiments [10] that is the subsets of genes that are
selected by feature selection technique varies across different subset of patients for the same
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disease, insufficient knowledge capture in tumor samples or the heterogeneity in tumor
samples [29]. Computational methods based on detecting differentially expressed genes
do not consider the dependencies or relationships between genes to accurately classify the
sample data; thus, identified gene biomarker sets may not contain driver genes or may
contain many differentially expressed genes with redundant information yielding decreased
prediction performance [21].
Network based methods that takes the knowledge of relation among genes into account
and generates more stable network-biomarkers than the gene biomarkers that can accurately
predict the outcome of breast cancer patient across different dataset [6] [2] [3] [8] [9] [36]. As
studies found that different protein and gene interaction plays an important role in cancer
molecular mechanism, network-biomarkers with one or more secondary network with gene
expression data gives more information for survivability of breast cancer patient. These
motivates us to find network-biomarkers than gene biomarkers to predict the survivability
of patients of different subtypes and treated with different combination of drugs.
1.4 Literature review
Network-biomarkers identification problem is a subset selection problem in which the se-
lected genes in a subset are functionally related. The best network-biomarkers are those
that discriminate the two classes of breast cancer and in our case the survival of patients
which means whether the breast cancer patient is going to survive or not. Most of the net-
work based approach starts with a seed gene as initial subnetwork and expand iteratively
from seed gene to its neighboring gene. The neighbor gene is generally added to the sub-
network based on improvement on some discriminative score of subnetwork with the newly
added gene.
In 2007, Chuang et al. [6] takes the knowledge of protein protein interaction network
with gene expression data to identify the network markers and predict the breast cancer
metastasis for patient. His identified subnetworks were actually meta-genes where each
meta-gene is a subnetwork in PPI and he showed that network-biomarkers increase the
classifiers accuracy between two datasets compared to gene expression biomarkers.
In 2011, P. Dao et al. proposed OptDis [8] a network based classification algorithm
that used color coding technique along with protein protein interaction network. They
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used OptDis for predicting response to drug and found it provides better and more stable
performance than other network based and gene based approach.
EB. van den Akker et al. [2] integrated protein protein interaction network along with
gene gene co expression network to predict breast cancer metastasis. For this study, they
used pair wise gene expression correlation measures to identify seed genes. To add the
information of PPI network and gene gene co-expression network, they applied different
integration approaches. Their method obtained the robustness of classifier performance as
their network-biomarkers works well across 6 different datasets.
K. Zhang et al. [37] devised a new method called CAERUS that integrates the infor-
mation of protein structure, protein-protein interaction networks and gene expression data.
They developed a scoring mechanism for each protein by considering domain connections to
its interacting partner and somatic mutation present in the domain. Then they identified
those gene signatures that have the score value above a predefined threshold. Then they
calculated the correlation of gene expression and its protein, and used Naive Bayes classifier
to predict the breast cancer carcinoma.This is the first predictive method to classify cancer
outcomes based on the relationship between domain organization and protein network.
Dutta et al. [9] identified network-biomarkers for predicting ER+, Her2+ and triple
negative breast cancer for patients. In their network they integrated the information of
gene expression and gene copy number data on protein-protein interaction, transcriptional-
regulatory and signalling networks. They also showed that their network based approach is
reproducible and functionally important.
D Wu et al. [36] showed that classifiers with knowledge on relation between genes
into account, improve robustness of classification performance and stability of detected
biomarkers. In 2014 Garcia et. al [11] proposed an interactome based approach that takes
copy number variation and protein protein interaction network into account and predicts
relapse free survival of breast cancer patient.
In 2015 A. Allahyar et al. [3] proposed FERAL. FERAL is based on sparse group lasso
that selects the genes for network during training. It uses the concept of metagenes by
summarizing multiple genes with different operators where each metagene is a subnetwork.




In this thesis, we propose a novel approach to identify network-biomarkers and predict
survivability of breast cancer patients. Our method is based on:
• chi square feature selection technique to identify seed genes
• subnetwork identification from PPI using Chuang et al’s approach
• chi square and forward feature selection with random forest algorithm to identify
metagenes that discriminate our classes.
• ADASYN to solve class imbalance within the data.
• random forest as classifier to predict survivability of breast cancer patients.
In this chapter, we discuss about some important terminology regarding breast cancer, what






We used the original METABRIC dataset [7] publicly available in cBioPortal [1]. The
dataset contains gene expression, copy number and somatic mutation data along with clin-
ical data (tumour morphology, ER and HER2 status, patient characteristics, treatment,
follow-data, survival status data) for 1904 patients. Among these patients, 480 of them
died for other reasons and we remove them from dataset that gives us 1,424 patients. For
predicting the survivability of the patients based on subtypes, we separate the data accord-
ing to ten different subtypes. As we have three types of therapy in the dataset that are
chemotherapy, hormone therapy and radio therapy, we obtain eight combination of these
therapies including a patient did not receive any therapy. For predicting the survivability
of the patient treated with any combination of these drug, we separate the dataset in eight
subsets based on treatment they received. Figure 2.1 shows the number of samples in each
subtype and in each combination of drug. The copy number aberration and copy number
variations were generated using Affymetrix SNP 6.0 arrays and gene expression data were
obtained using Illumina HT 12 technology. The dataset has 24,368 differentially expressed
genes.
Our PPI network contains 224,766 interactions with proteins. The protein protein inter-
action are gathered from a number of sources: BioGrid, Mint, InnateDB, PDB. We have in
total of 15,123 unique proteins and 14,845 genes that are mapped to one or more proteins.
We have 12, 962 genes that are common in our gene expression dataset and in PPI network.
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(b) Number of patients in each combination of ther-
apy.
FIGURE 2.1: Subtype and therapy specific samples.
2.2 Chi square
Chi square feature selection technique measures the degree of independence of each feature
classes. It uses the following formula:
χ2(Y,X) = N × (AD − CB)(A+ C)× (B +D)× (A+B)× (C +D) (2.1)
A is the number of times feature X in our case discretized gene expression X and class Y
that is survived or deceased co-occur. B is the number of times X occurs without Y. C is
the number of times Y occurs without X. D is the number of times neither X and Y occurs.
N is the total number of samples.
2.3 Obtaining Subnetwork from PPI
In our thesis, a subnetwork is a single connected component in protein protein interaction
network. For obtaining subnetworks from seed genes we implemented Chuang et. al [6]
approach.
Algorithm 1 shows how to obtain a subnetwork from PPI using a seed gene.Subnetwork
identification from seed gene is a greedy approach. Given a seed gene, we expand the
network with distance = 1 from seed gene protein and consider each child protein with
seed gene protein as separate network. We then calculate the activity score of each of the
8
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Input: Seed Gene, PPI, Gene Expression
Result: Subnetwork
Given a seed gene find corresponding proteins and add them to seed proteins list;
for each seed proteins do
initialize parent protein with seed protein;
initialize subnetwork with parent protein;
find all proteins with d = 1 from parent protein;
add them to other protein list;
for each other protein do






discretize activity score, a′;
Mutual information, MI(a′, c) = ∑xa′ ∑yc p(x, y)log p(x, y)p(x).p(y)
end
add protein that gives highest mutual information to subnetwork list;
add parent of the protein to parent protein list;
remove the protein from other protein list;
if distance from seed protein to recently added protein <maxdistance then
expand network with d = 1 from the added protin;
add these proteins to other protein list;
end




Algorithm 1: Subnetwork identification with a seed gene.
subnetwork and then discretize the activity score in equally spaced bins. The number of
bins is decided by blog2(number of samples) + 1c. We then calculate mutual information
for each of the subnetwork from the discretized mutual information based on class. We pick
the protein that has highest mutual information and again expand the subnetwork from
recently added protein with distance = 1 if the distance from the seed gene to recently
added protein is not greater than our intended distance. The process continues till there is
no improvement in mutual information or all the proteins are added to the subnetwork or
the mutual information is greater than 0.5.
Figure 2.2 shows an example subnetwork with a seed gene protein. The subnetwork
mentioned in the figure is a single connected component in the protein protein interaction
network. Each protein is mapped to a gene. Activity score that is calculated for a subnet-
work is a meta gene. So if we have k seed gene protein, we will obtain k subnetworks which
means we will obtain k metagene where each gene represents all the samples.
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FIGURE 2.2: Construction of a subnetwork with a seed gene protein.
Figure 2.3 shows the matrix that we will get with k seed gene proteins. Each row is a
metagene and each column is the sample of a patient. we used a similar matrix for each
subtype to identify network-biomarkers and predict survivability of breast cancer patient.
FIGURE 2.3: Matrix of samples and meta genes used for identification of network-
biomarkers and patient survival
Mutual Information






p(x, y)log p(x, y)
p(x).p(y) (2.2)
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Here x is each element of discretized activity score a′ and y is element of each class label
c. Higher value of mutual information indicates that it can separate the classes more than
the lower mutual information.
Discretization of Activity Score
We discretize the activity score by taking equally spaced bins. Number of bins are decided
by blog2(number of samples) + 1c. The distance of each bin is decided by the following
formula:
distance of each bin, δ = max value of activity score−min value of activity scorenumber of bins (2.3)
2.4 Forward Feature Selection
Forward feature selection is a wrapper method for selecting features from the dataset that
starts with empty set of features and iteratively add more features. Given a classification
algorithm which is random forest in our case, at first step, forward feature selection perform
classification m times if there are m features in the dataset and select the best feature. In
the next step, it again performs classification (m − 1) times as one feature is previously
selected and takes the feature that gives best performance when considered together with
previously selected feature or feature-set. The process continues until there is no further
improvement after adding additional features. We used 10-fold cross validation and bi-
directional search with forward feature selection to select the features that discriminate our
two classes. We used Weka [15] machine learning tool and take F1-measure as performance
evaluator.
2.5 P-Value
P-value indicates the statistical significance of a feature by null hypothesis test. The min-
imum value is zero and maximum value is 1. Smaller p-value indicates strong evidence
against null hypothesis while the larger p-value indicates opposite.
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2.6 ADASYN
ADASYN [17] is synthetic sample generating technique that generates more samples that
are hard to classify by reducing bias and using adaptive learning. Here, adaptive learning
means it generates more minority class samples from those minority class samples that
are hard to classify. The hard to classify minority class samples are those that have more
majority class samples in its k nearest neighbor. The algorithm first calculates the ratio
of majority class sample in K nearest neighbor of each minority class sample by using the
following formula:
ri = ∆i/K (2.4)
∆i is the number of majority class samples inK nearest neighbor of xi where xi minority class sample.





ms is the minority class samples. Then it calculates the number of samples needs to be
generated for each of the minority class samples
gi = rˆi ∗G (2.6)
G is the total number of samples that needs to be generated. The samples are generated
from the following formula:
si = xi + (xzi − xi) ∗ λ (2.7)
xzi is the minority class samples in K nearest neighbor of xi and λ is a random number
between 0 and 1.
We consider patient who decease as positive class and patients who survive as negative
class. If the ratio between positive and negative class is greater than or equal to 1:2 or
vice-versa, we consider those subsets of the data have class imbalance and apply ADASYN.
2.7 Random Forest
Random forest [4] is a tree based classifier that grows multiple classification trees to classify
a sample. If there are n samples in the training set, it randomly sample the data from
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n samples and grows a number of trees. At each node of the decision trees, it selects m
features in our case m genes randomly where m << M . M indicates total genes in the
dataset. The best split of these m is used to split the node. It then use voting to finally
assign class label: decease or survive to the sample. So if most of the trees classify the
sample as decease, the algorithm will classify the patient as decease and if most of the trees
classify the sample as survive the algorithm will classify the sample as survive. One of the
important task of random forest classifier is to optimize the number of features at each split
of the decision tree because the classifier’s performance may vary because of the number of
features at each split. For this purpose, we started with 1 features at each split and, trained
and tested with M −1 features and chose the model that gives best Geometric-Mean value.
We used the implementation of MATLAB’s Statistics and Machine Learning Toolbox for
random forest.
2.8 Logistic Regression
Logistic regression uses logistic or sigmoid function to predict the outcome of a sample. The
classifier tries to learn the following objective function:
p(y = 1|x) = 11 + exp(−θtx) = hθ(x) (2.8)
p(y = 0|x) = 1− p(y = 0|x) (2.9)
In the equations, y indicates class labels and x are the features. θ is the parameter we
need to find such that hθ(x) is large when x belongs to class 1 and small when x belongs
to class 2. To find θ we need to minimize following cost function:
J(θ) = −yloghθ(x) + (1− y)log(1− hθx) (2.10)
This cost function indicates how well our hypothesis hθ fits our training data.
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2.9 Our Method
We use chi square feature selection technique to identify the seed genes from gene expres-
sion and then using those seed genes we identify the subnetworks from PPI. The identified
subnetworks are the features for the next steps. We again use chi square and forward
feature selection with random forest to further reduce the number of subnetworks. While
using forward feature selection, we use 10-fold cross validation to obtain the features. After
identifying the network-biomarkers, we use those network biomarkers to predict the sur-
vivability of patients. If the ratio between survived and deceased patients is greater than
2:1, we apply ADASYN to generate synthetic samples for minority class samples and then
use random forest classifier to predict the survivability. If the ratio of samples of survived
and deceased class is less than 2:1 or vice versa, we directly use random forest classifier.
Figure 2.4 shows the steps invovled in our method.
FIGURE 2.4: Steps of involve in our method
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2.10 Chuang et al’s Method
Seed gene selection in Chuang et al’s method is based on common genes of two datasets.
As we have only one dataset, we apply Chuang et al’s method after seed gene selection
procedure. After identifying seed genes, they also identify subnetworks from PPI using seed
genes as initial network. Then they apply logistic regression to classify between classes and
choose feature based on increasing order of p-value. The classifier starts with one feature
and increase the number of features iteratively and finally select all those features that
achieve the best performance measure.
In this chapter we describe our method and algorithms used in our method such as chi
square, forward feature selection, random forest and metagene identification. We also de-




3.1 Identification of Network-biomarkers
First, we identified the seed genes for each subtype and each combination of therapy using
Chi square feature selection from gene expression dataset. So the seed genes are actually
genes in gene expression data that can discriminate survivability of patients. We consider
all the genes as seed genes that have Chi square value greater than zero. Table 3.1 and 3.2
show the number of genes that are identified as seed genes.
TABLE 3.1: Number of seed genes identi-













TABLE 3.2: Number of seed genes iden-
tified for each therapy combination by us-
ing Chi square feature selection
Therapy Combination Features
C 184
C & H 417
C & H & R 131
C & R 118
H 127
H & R 378
R 136
No Therapy 537
We build the subnetworks using distance 2, 3 and 4 separately for each subtypes and
combination of therapy following Chuang et al’s [6] approach described in methodology
section. These subnetworks are actually meta-genes and we use these metagenes as features.
If we have k seed genes we will atleast obtain k subnetworks. We may obtain more than
k subnetworks as sometimes a gene can be mapped to more than one protein and in that
case we will get more than one subnetworks for one seed gene. Table 3.3 shows the number
of subnetworks identified with seed gene.
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TABLE 3.4: Number of subnetworks ob-
tained in combination of therapy.
Therapy Combination Seed Genes
C 188
C & H 428
C & H & R 133
C & R 121
H 127
H & R 384
R 140
No Therapy 544
With our method, Chi square feature selection technique is applied again to further
reduce the number of features but this time we reduce the number of metagenes as we are
using subnetworks as our features. After applying Chi square and taking all the metagenes
that have Chi square value greater than zero, forward feature selection technique along with
random forest classifier is used to identify those metagenes that can discriminate the patients
who are going to survive and who are going to be deceased. We took F1-measure as evaluator
of our classifier while selecting features with Forward feature selection. Table 3.5 and 3.6
show number of identified network-biomarkers for each subtype and each combination of
therapy.
TABLE 3.5: Number of subnetworks for each subtype after applying Chi square and forward
feature selection.
Subtype Distance 2 Distance 3 Distance 4
1 25 28 30
2 42 35 34
3 34 47 41
4 57 55 60
5 29 30 31
6 28 37 38
7 46 55 54
8 65 70 73
9 28 30 29
10 46 47 55
Chuang et al’s method also starts with seed gene selection and he used two datasets to
find seed genes. As we do not have two datasets, his method is followed after seed gene
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TABLE 3.6: Number of subnetworks for each combination of therapy after applying Chi
square and forward feature selection.
Therapy Combination Distance 2 Distance 3 Distance 4
C 20 16 17
C & H 6 6 6
C & H & R 35 40 39
C & R 38 39 44
H 47 48 41
H & R 82 88 90
R 38 41 40
No therapy 74 84 91
selection. As subnetwork identification process of our method and his method are similar,
we obtain exactly same metagenes. After identifying the metagenes, p-value is calculated
for each of the feature and logistic regression classifier is trained and tested with 10-fold
cross validation. The features are added according to increasing order of p-values and select
those features that gives best performance measure. gmean is used as primary performance
measure. Table 3.7 and 3.8 show the number of metagenes selected using Chuang et al
approach.
TABLE 3.7: Number of subnetworks for each subtypes after selecting features based on
p-values following Chuang’s method.
Subtype Distance 2 Distance 3 Distance 4
1 3 3 3
2 6 14 10
3 4 18 18
4 81 83 68
5 8 8 8
6 4 4 4
7 8 5 5
8 28 19 14
9 53 8 18
10 19 18 18
3.2 Classifier Evalulators
To evaluate our classifier, we used 10 fold cross validation and as performance measure,
we used gmean, F1-measure, MCC, AUC and accuracy. As gmean is sensitive to class
imbalance and is often preferred over other performance measure if there is class imbalance
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TABLE 3.8: Number of subnetworks for each combination of therapy after selecting features
based on p-values following Chuang’s method
Therapy Combination Distance 2 Distance 3 Distance 4
C 5 22 27
C & H 2 3 3
C & H & R 54 2 11
C & R 11 5 9
H 5 16 4
H & R 56 13 13
R 11 4 114
No therapy 6 8 8
within the data, we consider gmean as our primary performance measure. We consider
patients who are deceased as positive class and patients who survived as negative class. We
also calculated overall performance measure of our classifier.
Accuracy is calculated by dividing all correctly classified breast cancer patient by total
samples in the subset. The formula for accuracy is given below:
Accuracy = TP + TN
TP + FN + FP + TN (3.1)
where TP = True Positive that is the sample is from positive class and it is classified
as postive class, FN = False Negative that is the sample is from positive class but it is
classified as negative class, FP = False Positive that is the sample is from negative class
but it is classified as positive class, TN = True Negative that is the sample is from negative
class and it is classified as negative class. F1-measure measures how well the positive class
is classified by considering positive predicted value (PPV) and sensitivity. It ranges from 0
to 1 where 1 indicates the perfect classifier. As we consider deceased patients as our positive
class, this performance measure will tell us how well we are predicting deceased patients.
F1-measure is calculated as follows:
F1-measure = 2× PPV × Sensitivity









Area Under Curve (AUC) gives us the tradeoff between true positive rate and false
positive rate in Receiver Operating Curve space where the values lies between 0 to 1.
1 indicates the perfect classifier. Geometric mean is the square root of sensitivity and
specificity. The formula is given below:
Gmean =
√
sensitivity × specificity (3.4)
where sensitivity is calculated using the formula showed in Equation 3.3 and specificity is
calculated by:
Specificity = TN
TN + FP (3.5)
As sensitivity and specificity captures how much samples in positive class and negative
class are classified correctly out of all the samples of positive class and negative class re-
spectively, it can be used as primary performance measure when the number of samples in
positive and negative class are not equal.
Mathews Correlation Coefficient (MCC) consider TP, TN, FN and FP and is sensitive
to class imbalance problem. Unlike other performance measures described above, it ranges
from -1 to 1 where 1 means perfect classifier and 0 means average case. The equation is
given below:
MCC = TP × TN − FP × FN√
(TP + FP )× (TP + FN)× (TN + FP )× (TN + FN) (3.6)
For calculating the overall performance o classifier based on subtype and therapy com-
bination, we followed Sokolova et. al’s approach [27]. We calculated overall TP, TN, FN




















In the Equation 3.7, l is indicating number of subtypes or number of combination of therapy.
3.3 Subtype Specific Survival Prediction
As we consider 10 subtypes, we predicted the survivability based on 10 subtypes and calcu-
lated their performance measure based on the technique described above. We implemented
our method and Chuang’s method in our dataset with distance 2, 3 and 4 from seed gene
protein. Table 3.9 to Table 3.9 show the performance measure for each subtype of our
method and Chuang et al.’s method. From the tables, we observe that our method has bet-
ter performance measure in all the cases except subtype five with distance 2 gmean value.
Though gmean in subtype five with distance2 is less than Chuang et. al’s approach, other
two performance measure we consider is larger than their approach. The red colored value
in the tables indicate the best performance measure obtained between the two methods.
We also compare how well our method performs overall compared to Chuang et al’s
method. We observe that for each distance we consider, our method performs better than
their method. Table 3.12 shows the comparison of performance measure for each distance.
From the table, we observe that with our dataset our method has significantly high perfor-
mance measure than their method and the difference between the performance measure is
almost 10% with all the distances. As we observe that, irrespective of distance, our method
performs better than Chuang’s method for subtype specific survival prediction, we compare
our method between different distances for each subtype to see which distance performs
better for which subtype. Table 3.13, 3.14, 3.15, 3.16, 3.17 show gmean, MCC, F1-measure,
AUC and accuracy of the classifier respectively. The red colored cells in the table indicate
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TABLE 3.9: Comparison of performance measure between Chuang et. al method and our














1 0.754 0.897 0.734 0.891 75.93% 89.81%
2 0.750 1 0.816 1 76.79% 100%
3 0.770 0.940 0.694 0.877 84.24% 92.39%
4 0.689 0.740 0.611 0.683 71.19% 79.84%
5 0.780 0.757 0.850 0.873 80.63% 82.50%
6 0.802 0.940 0.837 0.961 80.95% 95.24%
7 0.813 0.908 0.774 0.891 82.64% 91.74%
8 0.810 0.840 0.775 0.813 81.54% 85.64%
9 0.781 0.914 0.803 0.935 78.30% 92.45%
10 0.725 0.770 0.666 0.728 75.53% 81.38%
TABLE 3.10: Comparison of performance measure between Chuang et. al method and














1 0.731 0.908 0.718 0.903 73.15% 90.74%
2 0.777 1 0.828 1 78.57% 100%
3 0.777 0.927 0.686 0.859 82.61% 91.30%
4 0.653 0.733 0.568 0.675 67.49% 79.42%
5 0.767 0.790 0.833 0.896 78.75% 85.63%‘
6 0.802 0.947 0.837 0.960 80.95% 95.24%
7 0.807 0.860 0.766 0.829 81.82% 86.78%
8 0.801 0.857 0.764 0.834 81.03% 87.18%
9 0.794 0.914 0.826 0.935 80.19% 92.45%
10 0.748 0.774 0.695 0.734 77.13% 81.91%
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TABLE 3.11: Comparison of performance measure between Chuang et. al method and














1 0.731 0.907 0.718 0.902 73.15% 90.74%
2 0.763 0.986 0.811 0.985 76.79% 98.21%
3 0.770 0.940 0.694 0.897 84.24% 94.02%
4 0.678 0.725 0.598 0.662 69.14% 78.19%
5 0.767 0.797 0.833 0.895 78.75% 85.63%
6 0.802 0.960 0.837 0.973 80.95% 96.83%
7 0.807 0.884 0.766 0.860 81.82% 89.26%
8 0.788 0.825 0.750 0.794 80.51% 84.10%
9 0.795 0.906 0.803 0.926 79.25% 91.51%
10 0.748 0.782 0.695 0.742 77.13% 81.91%
TABLE 3.12: Comparison of overall performance measure between Chuang’s method and
our method for subtype specific survival prediction.


















the best value obtained by the classifier for that specific subtype and specific performance
measure. From the tables it is evident that, in most of the subtypes, we obtain best value
of different performance measure with distance 3 from the seed gene protein.
TABLE 3.13: Geometric mean for subtype specific survival prediction with our method.
Subtype Distance 2 Distance 3 Distance 4
1 0.897 0.908 0.907
2 1 1 0.986
3 0.940 0.927 0.940
4 0.740 0.733 0.725
5 0.757 0.790 0.797
6 0.940 0.947 0.960
7 0.908 0.860 0.884
8 0.840 0.857 0.825
9 0.914 0.914 0.906
10 0.770 0.774 0.782
TABLE 3.14: MCC for subtype specific survival prediction with our method.
Subtype Distance 2 Distance 3 Distance 4
1 0.795 0.815 0.814
2 1 1 0.962
3 0.832 0.807 0.857
4 0.550 0.540 0.512
5 0.615 0.692 0.689
6 0.904 0.901 0.935
7 0.825 0.721 0.773
8 0.699 0.732 0.667
9 0.850 0.850 0.830
10 0.602 0.615 0.613
TABLE 3.15: F1-measure for subtype specific survival prediction with our method.
Subtype distance 2 distance 3 distance 4
1 0.891 0.903 0.902
2 1 1 0.985
3 0.877 0.859 0.897
4 0.683 0.675 0.662
5 0.873 0.896 0.895
6 0.961 0.960 0.973
7 0.891 0.829 0.860
8 0.813 0.834 0.794
9 0.935 0.935 0.926
10 0.728 0.734 0.742
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TABLE 3.16: AUC for subtype specific survival prediction with our method.
Subtype Distance 2 Distance 3 Distance 4
1 0.918 0.965 0.968
2 1 1 0.997
3 0.973 0.958 0.972
4 0.850 0.861 0.852
5 0.912 0.932 0.919
6 0.993 0.997 0.997
7 0.962 0.955 0.956
8 0.935 0.949 0.937
9 0.969 0.969 0.980
10 0.868 0.871 0.882
TABLE 3.17: Accuracy for subtype specific survival prediction with our method.
Subtype Distance 2 (%) Distance 3 (%) Distance 4 (%)
1 89.81 90.74 90.74
2 100 100 98.21
3 92.39 91.30 94.02
4 79.84 79.42 78.19
5 82.50 85.63 85.63
6 95.24 95.24 96.83
7 91.71 86.78 89.26
8 85.64 87.18 84.10
9 92.45 92.45 91.50
10 81.38 81.91 81.91
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We also want to find which distance is the best with our method that gives best perfor-
mance of classifier. Though we observe that distance 3 has better performance evaluator
value in most of the subtypes, without calculating the overall performance measure we
cannot say that distance 3 is the best distance. Hence, we calculate overall performance
measure for each distance and compare them with each other. Figure 3.1 shows the overall
performance measure. Value above each bar indicates the value of the corresponding per-
formance evaluator. The red colored one indicates the best value. We observe that distance

























































FIGURE 3.1: Subtype specific overall performance measure of the classifiers based on
distance with our method.
3.4 Therapy Specific Survival Prediction
We have three therapies, that are chemotherapy, hormone therapy and radiotherapy. Thus
we got 8 combination of those including the patients did not receive any therapies. Here, we
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also compare our method with Chuang et al’s method. Table 3.18 to Table 3.20 show the
performance measure obtained using our approach and Chuang et al’s approach.From the
tables, we observe that their method gives better value of performance evaluator only for
chemotherapy and hormone therapy combination as Chuang et al’s method classify all the
patients correctly. For rest of the seven therapy combinations, our method outperforms their
method as we have better performance measure than theirs. The red colored value in the
tables show the best performance measure obtained for that specific therapy combination.
TABLE 3.18: Comparison of performance measure between Chuang et. al method and our
















C 0.939 0.970 0.935 0.969 93.94% 96.97%
C & H 1 1 1 1 100% 100%
C & H & R 0.718 0.842 0.651 0.809 73.73% 86.44%
C & R 0.788 0.866 0.740 0.842 80.15% 88.55%
H 0.713 0.804 0.666 0.772 72.58% 81.61%
H & R 0.703 0.754 0.653 0.713 72.13% 77.08%
R 0.729 0.846 0.763 0.877 73.55% 85.81%
No therapy 0.749 0.845 0.738 0.843 75.12% 84.51%
TABLE 3.19: Comparison of performance measure between Chuang et. al method and our
















C 0.939 0.970 0.941 0.969 93.94% 96.97%
C & H 1 0.925 1 0.923 100% 94.44%
C & H & R 0.637 0.897 0.552 0.873 71.19% 90.68%
C & R 0.772 0.866 0.721 0.847 79.39% 89.31%
H 0.702 0.805 0.653 0.774 71.94% 81.61%
H & R 0.684 0.748 0.627 0.704 71.46% 76.63%
R 0.716 0.846 0.751 0.877 72.26% 85.81%
No therapy 0.736 0.859 0.728 0.855 73.71% 85.92%
We calculate the overall performance measure to find which method performs well for
each distance. Table 3.21 shows the overall comparison for different distance between our
method and their method. We observe that irrespective of any distance, our method per-
forms better than their method for therapy combination. In most of the performance
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TABLE 3.20: Comparison of performance measure between Chuang et. al method and our
















C 0.909 0.970 0.909 0.969 90.91% 96.97%
C & H 1 0.925 1 0.923 100% 94.44%
C & H & R 0.661 0.867 0.582 0.837 72.03% 88.14%
C & R 0.750 0.888 0.693 0.872 77.10% 90.84%
H 0.686 0.810 0.629 0.780 71.94% 82.58%
H & R 0.684 0.760 0.627 0.721 71.46% 78.65%
R 0.727 0.836 0.750 0.874 72.90% 85.16%
No therapy 0.736 0.853 0.728 0.848 73.71% 85.45%
evaluator, our method gives almost 10% better performance evaluator value than theirs.
From our observation, we can say that with our dataset, our method outperforms Chuang
et al’s method for predicting survivability based on therapy combination.
TABLE 3.21: Comparison of overall performance measure between Chuang’s method and
our method for therapy specific survivability prediction.
















We built our network with three different distances from seed genes. Table 3.22 to
Table 3.26 show the comparison of performance measure we estimated using 10-fold cross
validation for different distances. From these tables, we can identify which distance performs
better for a specific therapy combination. We also observe that distance 3 and distance 4
outperforms distance 2 in most of the therapy combination. The red colored values indicates
the highest performance evaluated for the specific therapy combination.
We want to identify which distance gives better performance overall for predicting sur-
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TABLE 3.22: Gmean for each combination of therapy with our method.
Therapy Distance 2 Distance 3 Distance 4
C 0.970 0.970 0.970
C & H 1 0.925 0.925
C & H & R 0.842 0.897 0.867
C & R 0.866 0.866 0.888
H 0.804 0.805 0.810
H & R 0.754 0.746 0.760
R 0.846 0.846 0.836
No Therapy 0.845 0.859 0.853
TABLE 3.23: MCC for each combination of therapy with our method.
Therapy Distance 2 Distance 3 Distance 4
C 0.970 0.970 0.970
C & H 1 0.925 0.925
C & H & R 0.842 0.897 0.867
C & R 0.866 0.866 0.888
H 0.804 0.805 0.810
H & R 0.754 0.746 0.760
R 0.846 0.846 0.836
No Therapy 0.845 0.859 0.853
TABLE 3.24: F1-measure for each combination of therapy with our method.
Therapy Distance 2 Distance 3 Distance 4
C 0.969 0.969 0.969
C & H 1 0.923 0.923
C & H & R 0.809 0.873 0.837
C & R 0.842 0.847 0.872
H 0.772 0.774 0.780
H & R 0.713 0.704 0.721
R 0.877 0.877 0.874
No Therapy 0.843 0.855 0.848
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TABLE 3.25: AUC for each combination of therapy with our method.
Therapy Distance 2 Distance 3 Distance 4
C 1 1 1
C & H 1 1 1
C & H & R 0.918 0.935 0.935
C & R 0.957 0.953 0.946
H 0.874 0.860 0.893
H & R 0.825 0.820 0.820
R 0.925 0.925 0.939
No Therapy 0.902 0.902 0.896
TABLE 3.26: Accuracy for each combination of therapy with our method.
Therapy Distance 2 (%) Distance 3 (%) Distance 4 (%)
C 96.97 96.97 96.97
C & H 1 94.44 94.44
C & H & R 86.44 90.68 88.14
C & R 88.55 89.31 90.84
H 81.61 81.61 82.58
H & R 77.08 76.63 78.65
R 85.81 85.81 85.16
No Therapy 84.51 85.92 85.45
vivability of breast cancer patients based on therapy. Hence, we also calculated overall
performance measure for each distance. Figure 3.2 shows the overall performance measure
. From the figure, it is evident that distance 4 gives the best performance while distance
2 is the lowest one among the three. So distance 4 is the best distance among the three
distance for predicting therapy specific survivability of breast cancer patients.
3.5 Comparison between therapy and subtype specific method
If we compare our result between therapy specific survival prediction and subtype specific
survival prediction, we observe that subtype specific can better predicts the survivability
of breast cancer patients. Table 3.27 shows the comparison between them. We compare
between distance 3 subtype specific survivial and distance 4 therapy specific survival as
these two are the best in their own category with our method. While subtype specific
method has gmean: 0.867, MCC: 0.735, F1-measure: 0.850 and accuracy: 87.00%, therapy




























































FIGURE 3.2: Therapy specific overall performance measure of the classifiers based on
distance with our method.
TABLE 3.27: Comparison of performance measure between subtype specific and therapy
specific survival prediction with our method.







3.6 Identified Network biomarkers
We identified medium sized network-biomarkers where the maximum number of protein in a
subnetwork for subtype specific survival with distance 3 from seed gene protein is 77 and for
therapy specific survival with distance 4 from seed gene protein is 198. Figure A.31 shows the
network-biomarkers with distance 2 from seed gene protein. The self loop indicates the seed
gene protein. Protein name is mentioned beside each nodes of the network. Figure 3.4 shows
the mapped gene to its corresponding proteins. The maximum size of these subnetworks is
31. Rest of the subnetworks are added in the appendix. As some of the network-biomarkers








































































FIGURE 3.3: Identified network-biomarkers for chemotherapy received patients with dis-
tance 2 from seed gene proteins where nodes are proteins.
In this chapter, we discuss how we identify the network-biomarkers, compare between
our method and Chuang et. al’s method and also compare our method among different
distances of network from seed gene protein. We also compare between subtype specific










































































FIGURE 3.4: Identified network-biomarkers for chemotherapy received patients with dis-




As gene biomarkers are not stable and network-biomarkers based on functionally related
genes give stability to the biomarkers, we used a metagene based method where the genes
in a metagene are connected through protein protein interaction network. To build the
network, we initially start with seed genes and we take all genes as seed genes that have
chi square value greater than zero. This gives us all the genes that shows discriminative
behavior for predicting survivability of breast cancer patient. With these seed genes, we
then build metagenes using protein protein interaction network. Number of genes in a
metagene depends on the threshold of mutual information. We continue to add more genes
to the metagene until mutual information value goes above 0.5. If we decrease the threshold
to some other value, it will build small metagenes than ours. Increasing the threshold may
work as just opposite. We then use chi square feature selection technique to reduce the
number of metagenes for each subtype and each therapy combination and then use forward
feature selection with random forest classifier to obtain the network-biomarkers that can
predict whether a patient is going to survive or not. We use forward feature selection after
chi square feature selection because forward feature selection is computationally expensive.
If the number of features are high, it will take a lot of time to select features that discriminate
the classes. We also solve the class imbalance within the data if the ratio of samples between
two classes are greater than 1 : 2. If number of samples are not equal, classifiers tend to
become biased towards the class that has more samples. ADASYN helps us to solve this
problem as we applied ADASYN to generate synthetic samples. For predicting survivability,
we used a tree based classifier random forest which also works well if the samples of two
classes are not equal.
After obtaining metagenes we used chi square and forward feature selection for selecting
discriminative metagenes for our classes and use random forest as classifier while Chuang
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et. al used p-value for selecting features and logistic regression as classifier. We also address
the class imbalance within the subset of the data. Our method finds better discriminative
features as we used combination of filter and wrapper method. Logistic regression uses
sigmoid function while random forest is based on multiple decision trees. In this dataset,
the decision trees with the features we selected discriminate the classes better than sigmoid
function based logistic regression where p-value is used to rank the features.
We identified a number of metagenes for subtype and therapy specific survivability
prediction. We observe that subtype specific survivability prediction performs better than
therapy specific survivability prediction. This outcome is expected as each subtype of
breast cancer has different molecular mechanisms and these molecular mechanisms are not
considered when we consider therapy combination only.
In our dataset, we have very few samples for both classes in chemotherapy and, chemother-
apy and hormonetherapy combination. In chemotherapy, we have 17 patients who survived
and 16 patients who are deceased. In chemotherapy and hormonetherapy combination, we
have 11 patients who survived and 7 patients who are deceased. As we have very few sam-
ples in these two therapy combination, our classifier may suffer from under-fitting problem.
As our identified network-biomarkers are of medium size, number of genes that are needed
to discriminate survivability of patients are very high compared to gene expression based
study. This problem can be solved by optimizing mutual information value for metagene
identification. While predicting survivability based on subtypes, we did not consider therapy
combination as we have very few samples for different therapy combination in a subtype.
If we could consider therapy combination within a subtype, that may gives us better result




In this thesis, we devised a network based machine learning approach that can identify
network-biomarkers for predicting survivability of breast cancer patient a) based on sub-
types and b) based on therapy. Our method can also predict the survivability of breast
cancer patient based on a) subtypes and b) combination of therapy. our method is based
on a) integrating gene expression data with protein protein interaction network that allows
us to capture the knowledge required for predicting survivability b) devising an algorithm
which find the subnetworks that can best discriminate the classes and c) apply machine
learning method using the identified network-biomarkers to predict survivability. We use
distance 2, 3 and 4 from seed gene protein to identify network biomarkers and compare our
method with Chuang et al’s method and observe that our method obtain better performance
measure by almost 10% in all the cases. We also compare our method between different
distances we take for seed gene. We achieved 0.867, 0.735, 0.850 and 87.00% Geometric
Mean, Mathews Correlation Coefficient, F1-measure and accuracy for subtype specific with
distance 3 and 0.829, 0.669, 0.807, 83.77% Geometric Mean, Mathews Correlation Coef-
ficient, F1-measure and accuracy for distance 4 for therapy specific prediction of breast
cancer survivability. As subtypes of breast cancer represents more molecular mechanism,
we also observe that subtype specific prediction obtains better result than therapy specific
prediction for predicting survivability of patients.
5.1 Future Work
Our method can be further improved if we can consider therapy combination for each
subtype and predict the survivability based on therapy for each subtype. For this purpose,
we need a larger dataset that has enough samples for each combination of therapy. Another
way to improve our method is to add more information to our metagenes by considering
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gene’s mutation information or by adding secondary network. Gene’s mutation information
can be obtained from CNA. As a secondary network, we can consider some predefined
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FIGURE A.1: Identified network-biomarkers for subtype 1 distance 2 from seed gene pro-


































































































FIGURE A.2: Identified network-biomarkers for subtype 1 distance 3 from seed gene pro-










































































































FIGURE A.3: Identified network-biomarkers for subtype 1 distance 4 from seed gene pro-
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FIGURE A.4: Identified network-biomarkers for subtype 2 distance 2 from seed gene pro-













































































































FIGURE A.5: Identified network-biomarkers for subtype 2 distance 3 from seed gene pro-






































































































FIGURE A.6: Identified network-biomarkers for subtype 2 distance 4 from seed gene pro-
teins. The maximum size of a subnetwork is 10.
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FIGURE A.7: Identified network-biomarkers for subtype 3 distance 2 from seed gene pro-
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FIGURE A.8: Identified network-biomarkers for subtype 3 distance 3 from seed gene pro-
teins. The maximum size of a subnetwork is 28.
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FIGURE A.9: Identified network-biomarkers for subtype 3 distance 4 from seed gene pro-






































































































































































































FIGURE A.10: Identified network-biomarkers for subtype 4 distance 2 from seed gene



















































































































































































FIGURE A.11: Identified network-biomarkers for subtype 4 distance 3 from seed gene
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FIGURE A.12: Identified network-biomarkers for subtype 4 distance 4 from seed gene








































































































FIGURE A.13: Identified network-biomarkers for subtype 5 distance 2 from seed gene
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FIGURE A.14: Identified network-biomarkers for subtype 5 distance 3 from seed gene
proteins. The maximum size of a subnetwork is 20.
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FIGURE A.15: Identified network-biomarkers for subtype 5 distance 4 from seed gene






























































































FIGURE A.16: Identified network-biomarkers for subtype 6 distance 2 from seed gene
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FIGURE A.17: Identified network-biomarkers for subtype 6 distance 3 from seed gene
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FIGURE A.18: Identified network-biomarkers for subtype 6 distance 4 from seed gene
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FIGURE A.19: Identified network-biomarkers for subtype 7 distance 2 from seed gene
proteins. The maximum size of a subnetwork is 29.
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FIGURE A.20: Identified network-biomarkers for subtype 7 distance 3 from seed gene






































































































































































FIGURE A.21: Identified network-biomarkers for subtype 7 distance 4 from seed gene










































































































































































































FIGURE A.22: Identified network-biomarkers for subtype 8 distance 2 from seed gene


















































































































































































































































FIGURE A.23: Identified network-biomarkers for subtype 8 distance 3 from seed gene
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FIGURE A.24: Identified network-biomarkers for subtype 8 distance 4 from seed gene

















































































FIGURE A.25: Identified network-biomarkers for subtype 9 distance 2 from seed gene




































































































FIGURE A.26: Identified network-biomarkers for subtype 9 distance 3 from seed gene




























































































FIGURE A.27: Identified network-biomarkers for subtype 9 distance 4 from seed gene
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FIGURE A.28: Identified network-biomarkers for subtype 10 distance 2 from seed gene
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FIGURE A.29: Identified network-biomarkers for subtype 10 distance 3 from seed gene





















































































































































FIGURE A.30: Identified network-biomarkers for subtype 10 distance 4 from seed gene
proteins. The maximum size of a subnetwork is 16.
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A.2 Subnetworks for Therapy Specific Survival Prediction
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FIGURE A.31: Identified network-biomarkers for chemotherapy received patients with dis-






























































FIGURE A.32: Identified network-biomarkers for chemotherapy received patients with dis-




































































FIGURE A.33: Identified network-biomarkers for chemotherapy received patients with dis-





















FIGURE A.34: Identified network-biomarkers for chemotherapy and hormone therapy re-
























FIGURE A.35: Identified network-biomarkers for chemotherapy and hormone therapy re-






















FIGURE A.36: Identified network-biomarkers for chemotherapy and hormone therapy re-

























  P05452  P05783
  P08238
  P08476








































































































  9Y F1
FIGURE A.37: Identified network-biomarkers for chemotherapy, hormone therapy and ra-
diotherapy received patients with distance 2 from seed gene proteins. The maximum size






























































































































































FIGURE A.38: Identified network-biomarkers for chemotherapy, hormone therapy and ra-
diotherapy received patients with distance 3 from seed gene proteins. The maximum size










































































































































FIGURE A.39: Identified network-biomarkers for chemotherapy, hormone therapy and ra-
diotherapy received patients with distance 4 from seed gene proteins. The maximum size






















































































































































FIGURE A.40: Identified network-biomarkers for chemotherapy and radiotherapy received







































































































































































FIGURE A.41: Identified network-biomarkers for chemotherapy and radiotherapy received
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FIGURE A.42: Identified network-biomarkers for chemotherapy and radiotherapy received
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FIGURE A.43: Identified network-biomarkers for hormone therapy received patients with












































































































































































































FIGURE A.44: Identified network-biomarkers for hormone therapy received patients with
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FIGURE A.45: Identified network-biomarkers for hormone therapy received patients with
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FIGURE A.46: Identified network-biomarkers for hormone therapy and radiotherapy re-
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FIGURE A.47: Identified network-biomarkers for hormone therapy and radiotherapy re-
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FIGURE A.48: Identified network-biomarkers for hormone therapy and radiotherapy re-
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FIGURE A.49: Identified network-biomarkers for radiotherapy received patients with dis-
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FIGURE A.50: Identified network-biomarkers for radiotherapy received patients with dis-




















































































































































































FIGURE A.51: Identified network-biomarkers for radiotherapy received patients with dis-
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FIGURE A.52: Identified network-biomarkers for no therapy received patients with distance
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FIGURE A.53: Identified network-biomarkers for no therapy received patients with distance
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FIGURE A.54: Identified network-biomarkers for no therapy received patients with distance
4 from seed gene proteins. The maximum size of a subnetwork is 143.
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